Milestone Payments and Royalties. In consideration of the license granted under this Agreement, LICENSEE shall pay to BYU, in the manner designated below until the Agreement shall be terminated, as follows:
Milestone Payments and Royalties. The Milestone Payments and Royalties stated in this Agreement apply separately to the Initial Product and each New Product. The Parties may negotiate in good faith different research and development funding for each New Product than that provided for in Section V for the Initial Product according to the procedure stated below.
Milestone Payments and Royalties. The following provisions relate to milestone and royalty payments to be made by NWBio hereunder:
Milestone Payments and Royalties. Contingent on the each of the events described below, the following payments and royalties shall be paid by Corvas (within thirty (30) days of such event, except for royalty payments, which are payable pursuant to Section 4.5) to Incyte for each Drug Product(s) with respect to Designated Gene Products under respective license(s) as applicable:
Milestone Payments and Royalties. 5.01 SB agrees to make the following one-time milestone payments to ANTEX with respect to Product in the Field in the following amounts:
Milestone Payments and Royalties. Contingent on the following events, and subject to Sections 4.6 and 4.7, the following payments and royalties shall be paid by GHI (within thirty (30) days of such event) to Incyte for each Product with respect to Designated Gene/Gene Derivatives under respective license(s) as applicable. Remainder of the page intentionally left blank. *** Confidential material redacted and filed separately with the Commission. Table 4.2 Non-Exclusive Non-Exclusive Non-Exclusive License(s) under License(s) under License(s) under Incyte Know How or Incyte Know How or Incyte Know-How or Patent Rights – Patent Rights – Incyte Patent Personalized Homebrew Rights – Diagnostic Research Products in Products in Products in Homebrew FOU Diagnostic FOU Personalized Research FOU (Section 3.1.2& (Section 3.1.2& 3.1.3) 3.1.3) (Section 3.1.1) Product Stage Milestone $*** $*** $*** See (a) & (b) below Royalties on Net Sales ***% ***% ***% See (c) & (d) below
Milestone Payments and Royalties. LICENSEE shall pay LICENSOR milestone payments as follows:
Milestone Payments and Royalties. Prior to the commercialization of the Products, the Management Committee shall consider and if appropriate, determine reasonable royalties and milestone payments with respect to the commercialization of the Products by Newco that shall be payable by Newco to Elan and Photogen, and shared by Elan and Photogen [****] with Elan's and Photogen's [****] in Newco. At such time, the Management Committee will agree to an appropriate definition of "Net Sales" as such term is used in this Agreement.
Milestone Payments and Royalties. Prior to the commercialization of the Products, the Management Committee shall consider and if appropriate, determine reasonable royalties and milestone payments with respect to the commercialization of the Products by Newco that shall be payable by Newco to Elan and Photogen, and shared by Elan and Photogen [****] (whether common stock and/or preferred stock) in Newco. ---------------- ---------------- [****] REPRESENTS MATERIAL WHICH HAS BEEN REDACTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. At such time, the Management Committee will agree to an appropriate definition of "Net Sales" as such term is used in this Agreement.
Milestone Payments and Royalties. Following exercise of the Related Product Opt-In Right, Shire shall pay to Amicus royalty payments under Section 7.3 with respect to such Related Product as a Licensed Product. In addition, Shire shall pay to Amicus an additional set of Milestone payments for such Related Product, in an amount equal to [***] of the amounts for the achievement of the same events as provided for the first Licensed Product Developed for the same Field under Section 7.2.1, provided, that such payments shall not be due until the first Regulatory Approval of the first Licensed Product for the same disease within the Field as that of such Related Product. For clarity, upon Regulatory Approval of the first Licensed Product in a particular Field, payments for Milestones (as provided in this Section) for a Related Product previously achieved shall be due to Amicus.
